These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31350122)

  • 21. The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the Manchester driving behavior questionnaire.
    Biederman J; Fried R; Hammerness P; Surman C; Mehler B; Petty CR; Faraone SV; Miller C; Bourgeois M; Meller B; Godfrey KM; Baer L; Reimer B
    J Adolesc Health; 2012 Dec; 51(6):601-7. PubMed ID: 23174471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
    Lopez FA; Ginsberg LD; Arnold V
    Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating Attention-Deficit/Hyperactivity Disorder in Severe Intellectual Disability with Lisdexamfetamine: A Case Report.
    Araújo A; Madeira N; Ventura F; Morais S; Coroa M; Macedo A; Areias G; Borges J
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):490-492. PubMed ID: 34181364
    [No Abstract]   [Full Text] [Related]  

  • 26. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
    Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.
    Weisler R; Ginsberg L; Dirks B; Deas P; Adeyi B; Adler LA
    J Atten Disord; 2017 Dec; 21(14):1198-1207. PubMed ID: 24464328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex-Specific Long-Term Height and Body Mass Index Trajectories of Children Diagnosed with Attention-Deficit/Hyperactivity Disorder and Treated with Stimulants.
    Yackobovitch-Gavan M; Mimouni-Bloch A; Gabbay U; Carmi D; Goldstein B; Keinan-Boker L; Bloch S; Meyerovitch J
    J Pediatr; 2021 Nov; 238():296-304.e4. PubMed ID: 34293373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis.
    Stuhec M; Lukić P; Locatelli I
    Ann Pharmacother; 2019 Feb; 53(2):121-133. PubMed ID: 30117329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV; Glatt SJ
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of stimulant and non-stimulant drug treatment on driving performance in patients with attention deficit hyperactivity disorder: a systematic review.
    Gobbo MA; Louzã MR
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1425-43. PubMed ID: 25044052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
    Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Psychostimulants: An Overview].
    Fukumoto S; Imanari E; Tomari S; Higashi T; Kosaka H
    Brain Nerve; 2023 May; 75(5):599-604. PubMed ID: 37194538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of stimulant medication for adults with attention-deficit/hyperactivity disorder (ADHD) who are parents of adolescents with ADHD: the acute effects of stimulant medication on observed parent-adolescent interactions.
    Babinski DE; Waxmonsky JG; Waschbusch DA; Humphrey H; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):582-5. PubMed ID: 25386742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder.
    Gordon CT; Fabiano GA; Hulme KF; Sodano SM; Adragna M; Lim R; Stanford S; Janikowski L; Bufalo B; Rodriguez Z; Swiatek D
    Exp Clin Psychopharmacol; 2021 Aug; 29(4):308-318. PubMed ID: 32297783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response.
    Grebla R; Setyawan J; Park C; Richards KM; Nwokeji ED; Pawaskar M; Haim Erder M; Lawson KA
    J Med Econ; 2019 Aug; 22(8):788-797. PubMed ID: 30983465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.